263 related articles for article (PubMed ID: 27582777)
21. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.
Deckert A; Neuhann F; Klose C; Bruckner T; Beiersmann C; Haloka J; Nsofwa M; Banda G; Brune M; Reutter H; Rothenbacher D; Zeier M
PLoS One; 2017; 12(9):e0184766. PubMed ID: 28931037
[TBL] [Abstract][Full Text] [Related]
22. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
[TBL] [Abstract][Full Text] [Related]
23. Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors.
Liegeon G; Harrison L; Nechba A; Halue G; Banchongkit S; Nilmanat A; Yutthakasemsunt N; Pathipvanich P; Thongpaen S; Lertkoonalak R; Althaus T; Lallemant M; Mary JY; Jourdain G
J Infect; 2019 Nov; 79(5):454-461. PubMed ID: 31401085
[TBL] [Abstract][Full Text] [Related]
24. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Gallant JE; Winston JA; DeJesus E; Pozniak AL; Chen SS; Cheng AK; Enejosa JV
AIDS; 2008 Oct; 22(16):2155-63. PubMed ID: 18832879
[TBL] [Abstract][Full Text] [Related]
25. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
26. Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia.
Joshi K; Boettiger D; Kerr S; Nishijima T; Van Nguyen K; Ly PS; Lee MP; Kumarasamy N; Wong W; Kantipong P; Cuong DD; Kamarulzaman A; Choi JY; Zhang F; Chaiwarith R; Ng OT; Kiertiburanakul S; Sim BLH; Merati TP; Yunihastuti E; Ditangco R; Ross J; Pujari S
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1209-1216. PubMed ID: 30246898
[TBL] [Abstract][Full Text] [Related]
27. Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
Bregigeon S; Solas C; Faucher O; Obry-Roguet V; Tamalet C; Poizot-Martin I
Antivir Ther; 2017; 22(6):529-533. PubMed ID: 28195560
[TBL] [Abstract][Full Text] [Related]
28. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
30. Renal Adverse Effects of Tenofovir Containing Regimens in HIV-Infected Children and Adolescents in North India.
Kumar R; Singh MV; Shrivastava A; Yadav RK; Siddiqui SA; Sachan R; Maurya M; Mishra N; Shukla SK; Sonkar M
Indian Pediatr; 2024 Apr; 61(4):337-342. PubMed ID: 38449277
[TBL] [Abstract][Full Text] [Related]
31. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study.
Nyende L; Kalyesubula R; Sekasanvu E; Byakika-Kibwika P
BMC Nephrol; 2020 Jun; 21(1):232. PubMed ID: 32571236
[TBL] [Abstract][Full Text] [Related]
34. Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.
Bonjoch A; Echeverría P; Perez-Alvarez N; Puig J; Estany C; Clotet B; Negredo E
Biomed Res Int; 2016; 2016():4380845. PubMed ID: 28078289
[No Abstract] [Full Text] [Related]
35. Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury.
Samuels R; Bayerri CR; Sayer JA; Price DA; Payne BAI
AIDS; 2017 Jun; 31(9):1297-1301. PubMed ID: 28323756
[TBL] [Abstract][Full Text] [Related]
36. Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
Marcelin JR; Berg ML; Tan EM; Amer H; Cummins NW; Rizza SA
PLoS One; 2016; 11(2):e0149562. PubMed ID: 26872144
[TBL] [Abstract][Full Text] [Related]
37. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
Baxi SM; Scherzer R; Greenblatt RM; Minkoff H; Sharma A; Cohen M; Young MA; Abraham AG; Shlipak MG;
AIDS; 2016 Feb; 30(4):609-18. PubMed ID: 26558723
[TBL] [Abstract][Full Text] [Related]
38. Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya.
Karoney MJ; Koech MK; Njiru EW; Owino Ong'or WD
PLoS One; 2022; 17(9):e0273183. PubMed ID: 36108078
[TBL] [Abstract][Full Text] [Related]
39. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
40. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Gupta SK; Post FA; Arribas JR; Eron JJ; Wohl DA; Clarke AE; Sax PE; Stellbrink HJ; Esser S; Pozniak AL; Podzamczer D; Waters L; Orkin C; Rockstroh JK; Mudrikova T; Negredo E; Elion RA; Guo S; Zhong L; Carter C; Martin H; Brainard D; SenGupta D; Das M
AIDS; 2019 Jul; 33(9):1455-1465. PubMed ID: 30932951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
